#United States #Chicago #Prenosis #Bobby Reddy #Sepsis ImmunoScore

Bobby Reddy, Jr. Makes Waves on TIME's 2025 TIME100 Health List

On May 8, 2025, it was announced that Bobby Reddy, Jr., the CEO and co-founder of Prenosis, Inc., has secured his place on TIME's esteemed 2025 TIME100 Health List. This recognition celebrates the 100 most influential figures in the health sector, and Reddy's inclusion underscores his pivotal role in advancing healthcare through technology.

Prenosis, a leader in the field of precision diagnostics powered by artificial intelligence, has been at the forefront of developing innovative solutions aimed at enhancing patient care. Under Reddy's visionary leadership, the company has integrated cutting-edge machine learning technologies with biological insights, primarily focusing on the early detection and management of severe conditions like sepsis.

Reddy remarked, "Receiving recognition on the TIME100 Health list is an incredible honor, but it is a testament to the hard work of the entire Prenosis team. Our primary goal has consistently been to improve health outcomes by personalizing treatment according to each patient's unique biological makeup. This acknowledgment reinforces the significance of our mission to use AI in addressing critical healthcare challenges, especially in the fight against sepsis, which is a leading cause of mortality in hospitals across the world."

Since establishing Prenosis in 2014, Reddy has demonstrated unwavering commitment to fostering the company's growth. He has successfully attracted investments, forged strategic partnerships with significant healthcare organizations, and facilitated commercial collaborations, notably with Roche.

One of Prenosis's flagship innovations, the Sepsis ImmunoScore™, was awarded the title of TIME Best Invention in 2024. This groundbreaking tool has shown exceptional accuracy in identifying patients at risk of sepsis well before traditional symptoms surface, which has the potential to save countless lives annually. With its implementation, healthcare professionals can utilize personalized patient data to make quicker and more precise treatment decisions for patients in critical situations.

The process of selecting the 2025 TIME100 Health honorees involved meticulous evaluation by TIME editors, who considered the individuals' impact, innovative approaches, and influence on tackling significant health issues. Those celebrated include key figures from the private sector, government, academia, research, and even the entertainment industry. The complete list and accompanying tributes will be available in the May 26, 2025, issue of TIME, which hits newsstands on May 16 and can also be accessed online at time.com/time100health.

About Prenosis, Inc.

Prenosis, Inc. is pioneering the realm of artificial intelligence in precision medicine for acute care. The company emphasizes that healthcare should be customized according to individual biological parameters. By employing a data-driven strategy in the dynamic field of acute medicine, Prenosis is ushering in a robust new era of healthcare precision. Their Immunix™ precision medicine platform provides proprietary biological insights that enhance the development of specialized products and facilitate the real-time delivery of optimal therapies. This includes the Sepsis ImmunoScore™, recognized as the first FDA-authorized AI tool for identifying sepsis risk. To learn more about Prenosis, visit www.prenosis.com.